Margarida Azevedo, MSc,  —

In a recent study titled “Senataxin suppresses the antiviral transcriptional response and controls viral biogenesis,” published in the journal Nature Immunology, researchers at Mount Sinai Hospital/Mount Sinai School of Medicine found that a human protein called senataxin (SETX), which has been found to…

Pharmaceutical company AB Science SA received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy for amyotrophic lateral sclerosis (ALS), called masitinib. The drug is a protein kinase inhibitor (PKI) and was granted the status in order to accelerate its…

A recent study from Sweden’s KTH Royal Institute of Technology (KTH) revealed three proteins that are associated with the progress of amyotrophic lateral sclerosis (ALS). The research team from the KTH and Science for Life Laboratory led by Anna Häggmark believe that the research is the most comprehensive plasma…

Massachusetts-based pharmaceutical company Biogen Idec Inc. has decided to rebrand the company with a shorter name and a new logo, as well as by refocusing its work and abandoning its near exclusivity to multiple sclerosis (MS) drugs to also include research on conditions such as amyotrophic lateral sclerosis (ALS).

A research team at Penn Medicine recently found that hypermethylation is able to inhibit the development of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD) in a study titled, “C9orf72 promoter hypermethylation is neuroprotective: Neuroimaging and neuropathologic evidence.” The results are published in the journal…

Results from a recent Phase I clinical trial in patients with Amyotrophic Lateral Sclerosis (ALS) showed a safe cell therapy approach that may allow for the treatment of larger pools of patients for later-phase ALS trials. The study is published in the Journal of Translational Medicine.

The ALS Association is inaugurating its new Nevada Chapter after the group joined 39 affiliates throughout the country to work in collaboration with the local community in order to support finding effective treatments and a cure for amyotrophic lateral sclerosis (ALS). The National Board of Trustees of the association recently praised…

The Augie’s Quest initiative is hosting a 10 Year Reunion Bash on Friday, March 13. The event, which is being organized together with the 34th Annual IHRSA Tradeshow and Convention is taking place at the JW Marriott, in Los Angeles, California and the funds raised are going to be used to support the ALS Therapy Development…

‘My-own-voice,’ a system for patients who are losing their ability to speak due to diseases such as amyotrophic lateral sclerosis (ALS) to record and later use their voice to communicate, was presented at the Annual International Technology and Persons with Disabilities Conference (CSUN). The Acapela…

A new Phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT01938495) titled “Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)” is examining the efficacy of DPS compared to standard of care in patients with ALS,…